M
Medi futures
Biomedical ultrasound company
About Medi futures
Medi Futures operates in the biotechnology sector, focusing on ultrasonic technology to improve human vision and cosmetic procedures. The company serves a diverse range of clients, including medical professionals, hospitals, and cosmetic clinics. Medi Futures is based in Korea, with its head office in Seongnam and a lab factory in Bucheon. The company's business model revolves around the development and commercialization of advanced ultrasonic devices and biotechnological solutions. Revenue is generated through the sale of these high-tech products and through partnerships for clinical research. Medi Futures is known for its innovative products like the DAVINCI COG, ULTRA SERIES, and ULTRA FILL COSMETICS, which are designed to offer safe, excellent, and innovative solutions for better life quality. The company is also engaged in clinical research, as evidenced by its MOU with Soonchunhyang University Hospital Bucheon for research on ultrasound-based adipose stem cell separation technology and 3D sutures.
Source: Dealroom company dataNews
Open roles
Medi futures in the Seongnam-si ecosystem
The Medi futures office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
SGI Venture Capital
DS Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Medi futures on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Medi futures on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

